New Mechanisms to Control Bone Loss: An Update for Managed Care Pharmacists
The contents of this issue of University of Tennessee Advanced Studies in Pharmacy include 4 review articles.
Activity Date: October 2008  — Activity Info: Volume5, (7)
Goals & Objectives | Faculty | Complete Pre-Test Activity | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired)


To provide managed care pharmacists with up-to-date information regarding their role in the diagnosis and management of patients with osteoporosis. 

This activity is designed for managed care pharmacists. No prerequisites required.

The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CE activity. At the conclusion of this activity, the participant should be able to:

  • Recognize individuals at risk for osteoporosis and the importance of initiating the appropriate therapy, in addition to recognizing the importance of promoting general bone health.
  • Translate knowledge of the receptor activator of nuclear factor-kB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway and how various diseases, hormones, and medications use this pathway to affect bone remodeling into improved management of osteoporosis.
  • Use current guidelines to practice evidence-based medicine in the care of patients with osteoporosis.
  • Evaluate new and emerging therapies for effectiveness as they relate to the RANK/RANKL/OPG pathway.

The University of Tennessee College of Pharmacy (UTCOP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) to provide continuing education for pharmacists.

acpe logoThis knowledge-based program is sponsored by The University of Tennessee College of Pharmacy who is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this program will provide 2 contact hours credit (0.2 CEUs). Successful completion includes reading the materials, completing the post-test with a score of at least 70%, and completing the program evaluation. If you score less than 70% on the post-test, you will be allowed to complete the post-test 1 more time. A statement of CE credit will be available online immediately following successful completion of the program. ACPE program # 064-000-08-209-H01-P.

This continuing education activity was produced under the supervision of Glen E. Farr, PharmD, Associate Dean for Continuing Pharmacy Education, University of Tennessee College of Pharmacy.

The estimated time to complete this educational activity: 2 hours.

Release date: October 15, 2008. Expiration date: October 15, 2010.

The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of a program sponsored or co-sponsored by the UTCOP may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.

This activity is supported by an educational donation provided by Amgen Inc.

Home | Contact Us | View Account | Need Help?